Related Experiment Video
Updated: May 30, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[Obesity and chronic kidney disease].
Terapevticheskii Arkhiv
|July 27, 2011
Summary
Obesity is a major risk factor for chronic kidney disease (CKD), causing significant kidney damage. Weight loss can improve kidney function and reduce the incidence of CKD.
Area of Science:
- Nephrology
- Endocrinology
- Epidemiology
Context:
- Obesity and overweight are recognized as global epidemics.
- Body weight is directly linked to functional and structural kidney alterations.
- Epidemiological data confirm obesity as a chronic kidney disease (CKD) risk factor, independent of other conditions like diabetes or hypertension.
Purpose:
- To elucidate the relationship between obesity and the development of chronic kidney disease (CKD).
- To identify the specific renal pathologies and underlying mechanisms linking obesity to nephropathy.
- To assess the impact of weight reduction on renal function in obese individuals.
Summary:
- Obesity-associated nephropathy manifests as microalbuminuria, proteinuria, hyperfiltration, or impaired renal function.
- Key structural changes include glomerulomegaly and focal segmental glomerulosclerosis.
- Mechanisms involve adipokine dysregulation, renin-angiotensin system activation, inflammation, endothelial dysfunction, and altered renal hemodynamics.
Impact:
- Weight reduction through lifestyle changes or bariatric surgery significantly reduces albuminuria and hyperfiltration.
- Obesity prevention and management are crucial for reducing the overall incidence of CKD.
- Understanding these links can inform public health strategies for kidney disease prevention.
More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
06:16White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...